Exact Sciences price target raised to $110 from $105 at BofA

BofA analyst Derik de Bruin raised the firm’s price target on Exact Sciences to $110 from $105 and keeps a Buy rating on the shares after the company reported Q2 upside and raised the midpoint of its FY23 revenue guidance range on the back of the “strong” Q2 print and expectations for continued momentum. The firm has raised its own estimates and remains positive on Exact’s core business and upcoming catalysts, the analyst tells investors in a post-earnings note.